Figure S2 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

Effective treatment strategy targets pancreatic cancer with MTAP deletion using PRMT5 and KRAS inhibitors.
In vivo analysis demonstrates significant efficacy in treatment, suggesting potential for broader application in cancer therapy.
Utilizing combined inhibitors aims to overcome challenges in treating KRAS-mutant pancreatic cancer, demonstrating new therapeutic avenues.
Further research may validate this combined strategy in clinical settings, highlighting its importance for addressing treatment-resistant cancer types.

We only have this paper's title and publication details.

In vivo analysis reveals effective treatment strategy for pancreatic cancer with MTAP deletion, indicating promise for KRAS inhibitors.

Figure S2 shows in vivo analysis of PRMT5i treatment.

No takes yet. Share an insight, caveat, or question.

Drizyte‐Miller et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share